BioAtla, Inc. (BCAB) - Quarterly EPS earnings growth

Official company branding of BioAtla Inc (BCAB)

BioAtla, Inc. (BCAB) maintains a high scientific reputation due to its development of antibodies activated within the tumor environment to reduce toxicity. This quarterly earnings per share chart illustrates financial stability, where 101.80 serves as the current metric level. Management is focusing on therapy selectivity to minimize side effects while adhering to strict environmental regulations for the disposal of laboratory reagents.

BioAtla (BCAB) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 09/06/2026

Analytical breakdowns for BioAtla, Inc.

- market value and analyst target forecast:
Price Chart bioatla.com|BCAB - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization BioAtla Corp|BCAB - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share BioAtla|BCAB - Total Stockholders' Equity|Market Value to Book Value Ratio bioatla.com|BCAB - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity BioAtla, Inc.|BCAB - Long-Term Liabilities to Capital|Short-Term Debt to Capital bioatla.com|BCAB - Company Total Indebtedness|Debt to Book Value BioAtla Corp|BCAB - Long-Term Debt|Company Current Liabilities BioAtla|Quick Liquidity Indicator bioatla.com
- earnings and market multiples details:
BCAB - Profit After Payment of Taxes|Projected Future Earnings BioAtla, Inc.|BCAB - Company Value to Net Income|Forward P/E Multiple bioatla.com|BCAB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioAtla Corp|BCAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BioAtla|BCAB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months bioatla.com|BCAB - Earnings per share trend in current year|Expected earnings per share growth for next year BioAtla, Inc.
Fundamental company analysis:BioAtla Inc, BCAB
Manufactured product of BioAtla, Inc.

This indicator measures the percentage change in net earnings per share between the current and corresponding previous quarter, allowing for an assessment of the dynamics of shareholder value generation. By analyzing the growth rate of quarterly earnings per share, an investor can see the impact of the colossal FDA clinic costs for BioAtla, Inc. (BCAB), which are temporarily suppressing profitability despite the exceptional defensive qualities of the CAB technology.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology Holdings)|CTXR (citiuspharma.com) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com